Eli Lilly
Eli Lilly and Company:Drug Development Strategy
Assignment One
RSM494: Technological Strategy
2/16/2012
Antora Sanchari Ahmed
997292139
Professor Terry Amburgey
TABLE OF CONTENTS
Executive Summary………………………………………………………………………..3
Market Analysis……………………………………………………………………………4
Industry Analysis………………………………………………………………………….5
Product and Process Analysis…………………………………………………………….7
Company Strategy………………………………………………………………………...9
Recommendations………………………………………………………………………..11
Conclusion………………………………………………………………………………..13
EXECUTIVE SUMMARY
This case outlines the difficulty faced by Eli Lilly, a pharmaceutical company’s decision as to whether they should develop a lead migraine compound. This decision is faced by the Project Manager Bianca Sharma and she has to make recommendations in the PTAC meeting. A number of things have to be considered like- time to market, diversity of leads, traditional or combinatorial chemistry etc. which is unique to the pharmaceutical industry. Other factors which might not be unique to this industry but still has to be considered in this analysis are- intellectual property (IP), funding for clinical trials, reliability of the product and process, alternatives to the product, firm’s short term and long term strategy, market conditions etc.
Eli Lilly’s success depends on their ability to strategize their next move regarding the development of this lead compound and exploiting the opportunities by careful considerations and then choosing the best option among the following:
Scenario 1: Take the lead compound into clinical without further research and race it to the market.
Scenario 2: Take some additional time to refine the current lead (using combichem) and then release to clinicals.
Assignment One
RSM494: Technological Strategy
2/16/2012
Antora Sanchari Ahmed
997292139
Professor Terry Amburgey
TABLE OF CONTENTS
Executive Summary………………………………………………………………………..3
Market Analysis……………………………………………………………………………4
Industry Analysis………………………………………………………………………….5
Product and Process Analysis…………………………………………………………….7
Company Strategy………………………………………………………………………...9
Recommendations………………………………………………………………………..11
Conclusion………………………………………………………………………………..13
EXECUTIVE SUMMARY
This case outlines the difficulty faced by Eli Lilly, a pharmaceutical company’s decision as to whether they should develop a lead migraine compound. This decision is faced by the Project Manager Bianca Sharma and she has to make recommendations in the PTAC meeting. A number of things have to be considered like- time to market, diversity of leads, traditional or combinatorial chemistry etc. which is unique to the pharmaceutical industry. Other factors which might not be unique to this industry but still has to be considered in this analysis are- intellectual property (IP), funding for clinical trials, reliability of the product and process, alternatives to the product, firm’s short term and long term strategy, market conditions etc.
Eli Lilly’s success depends on their ability to strategize their next move regarding the development of this lead compound and exploiting the opportunities by careful considerations and then choosing the best option among the following:
Scenario 1: Take the lead compound into clinical without further research and race it to the market.
Scenario 2: Take some additional time to refine the current lead (using combichem) and then release to clinicals.